Rua Bioscience Ltd
NZX:RUA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.023
0.12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches NZD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Rua Bioscience Ltd
Rua Bioscience Ltd
Cash & Cash Equivalents
Rua Bioscience Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Rua Bioscience Ltd
NZX:RUA
|
Cash & Cash Equivalents
NZ$895.1k
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
BLIS Technologies Ltd
NZX:BLT
|
Cash & Cash Equivalents
NZ$4.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
A
|
AFT Pharmaceuticals Ltd
NZX:AFT
|
Cash & Cash Equivalents
NZ$10.7m
|
CAGR 3-Years
22%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Cannasouth Ltd
NZX:CBD
|
Cash & Cash Equivalents
NZ$2.3m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
G
|
Greenfern Industries Ltd
NZX:GFI
|
Cash & Cash Equivalents
NZ$849.4k
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
Rua Bioscience Ltd
Glance View
Rua Bioscience Ltd. operates as a pharmaceutical company that develops medical cannabis products. The company is headquartered in Gisborne, Gisborne. The company went IPO on 2020-10-22. The firm operate in the medicinal cannabis sector commercially and is focused on producing cannabinoid derived medicines. The firm is also focusing on cultivating and developing quality-assured medicinal cannabis as active pharmaceutical ingredients.
See Also
What is Rua Bioscience Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
895.1k
NZD
Based on the financial report for Jun 30, 2024, Rua Bioscience Ltd's Cash & Cash Equivalents amounts to 895.1k NZD.
What is Rua Bioscience Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-27%
Over the last year, the Cash & Cash Equivalents growth was -65%. The average annual Cash & Cash Equivalents growth rates for Rua Bioscience Ltd have been -36% over the past three years , -27% over the past five years .
You don't have any saved screeners yet
